Q2 2024 EPS Estimates for uniQure (NASDAQ:QURE) Reduced by Analyst

uniQure (NASDAQ:QURE) – Equities researchers at William Blair lowered their Q2 2024 earnings per share (EPS) estimates for shares of uniQure in a report issued on Tuesday, May 7th. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings per share of ($1.16) for the quarter, down from their previous forecast of ($1.12). The consensus estimate for uniQure’s current full-year earnings is ($4.49) per share. William Blair also issued estimates for uniQure’s Q3 2024 earnings at ($1.18) EPS, Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($4.89) EPS, Q1 2025 earnings at ($1.20) EPS, Q2 2025 earnings at ($1.21) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.13) EPS and FY2025 earnings at ($4.66) EPS.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a report on Wednesday. The Goldman Sachs Group cut uniQure from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 price objective on shares of uniQure in a research report on Tuesday, January 16th. StockNews.com upgraded uniQure to a “sell” rating in a research report on Friday, March 1st. Finally, Mizuho lowered their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $31.91.

uniQure Trading Up 1.5 %

Shares of uniQure stock opened at $4.89 on Thursday. The business has a fifty day simple moving average of $5.00 and a two-hundred day simple moving average of $5.88. uniQure has a 1 year low of $4.25 and a 1 year high of $22.48. The company has a market capitalization of $233.93 million, a price-to-earnings ratio of -0.75 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a current ratio of 8.85 and a quick ratio of 8.68.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The business had revenue of $6.69 million during the quarter, compared to the consensus estimate of $3.20 million.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 15,906 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.38, for a total value of $101,480.28. Following the transaction, the chief financial officer now owns 116,948 shares in the company, valued at $746,128.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Christian Klemt sold 15,906 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.38, for a total value of $101,480.28. Following the transaction, the chief financial officer now owns 116,948 shares in the company, valued at $746,128.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 27,904 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the transaction, the chief executive officer now owns 440,839 shares in the company, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,265 shares of company stock worth $339,845. Company insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Hedge funds have recently made changes to their positions in the stock. Citigroup Inc. grew its holdings in shares of uniQure by 667.9% during the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company’s stock worth $5,143,000 after purchasing an additional 666,696 shares during the last quarter. Algert Global LLC grew its holdings in uniQure by 237.6% during the 3rd quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company’s stock worth $2,780,000 after acquiring an additional 291,541 shares during the last quarter. Vontobel Holding Ltd. increased its position in uniQure by 458.5% in the 4th quarter. Vontobel Holding Ltd. now owns 295,042 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 242,214 shares during the period. Jump Financial LLC bought a new position in shares of uniQure during the third quarter valued at $823,000. Finally, Swiss National Bank lifted its holdings in shares of uniQure by 8.0% during the third quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company’s stock worth $667,000 after purchasing an additional 7,400 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.